ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
ReShape Lifesciences (RSLS) has entered an exclusive U.S. distribution agreement with Motion Informatics to import and distribute neuromuscular rehabilitation devices. The partnership's flagship product is the FDA-cleared Stimel-03, which combines Functional Electrical Stimulation, Neuromuscular Electrical Stimulation, and real-time EMG biofeedback in a single platform.
The system is designed for patients recovering from stroke, injury, or surgery, and can be used in both clinical and home settings. Motion Informatics is also developing Spatial StimelMD (SSMD), a next-generation platform that incorporates AI-personalized neuromodulation, EMG biofeedback, and augmented reality for adaptive rehabilitation.
ReShape Lifesciences (RSLS) ha stipulato un accordo di distribuzione esclusivo negli Stati Uniti con Motion Informatics per importare e distribuire dispositivi di riabilitazione neuromuscolare. Il prodotto di punta della partnership è il Stimel-03, approvato dalla FDA, che combina Stimolazione Elettrica Funzionale, Stimolazione Elettrica Neuromuscolare e biofeedback EMG in tempo reale in un'unica piattaforma.
Il sistema è progettato per pazienti in fase di recupero da ictus, infortuni o interventi chirurgici, ed è utilizzabile sia in contesti clinici che domestici. Motion Informatics sta inoltre sviluppando il Spatial StimelMD (SSMD), una piattaforma di nuova generazione che incorpora neuromodulazione personalizzata tramite intelligenza artificiale, biofeedback EMG e realtà aumentata per una riabilitazione adattiva.
ReShape Lifesciences (RSLS) ha firmado un acuerdo de distribución exclusivo en EE. UU. con Motion Informatics para importar y distribuir dispositivos de rehabilitación neuromuscular. El producto insignia de la asociación es el Stimel-03, aprobado por la FDA, que combina Estimulación Eléctrica Funcional, Estimulación Eléctrica Neuromuscular y biofeedback EMG en tiempo real en una sola plataforma.
El sistema está diseñado para pacientes en recuperación de un accidente cerebrovascular, lesión o cirugía, y se puede utilizar tanto en entornos clínicos como en el hogar. Motion Informatics también está desarrollando el Spatial StimelMD (SSMD), una plataforma de próxima generación que incorpora neuromodulación personalizada mediante inteligencia artificial, biofeedback EMG y realidad aumentada para una rehabilitación adaptativa.
ReShape Lifesciences (RSLS)는 Motion Informatics와 독점적인 미국 유통 계약을 체결하여 신경근 재활 장비를 수입하고 배포합니다. 파트너십의 주력 제품은 FDA 승인을 받은 Stimel-03으로, 기능적 전기 자극, 신경근 전기 자극 및 실시간 EMG 바이오피드백을 단일 플랫폼에 통합합니다.
이 시스템은 뇌졸중, 부상 또는 수술에서 회복 중인 환자를 위해 설계되었으며, 임상 및 가정 환경 모두에서 사용할 수 있습니다. Motion Informatics는 또한 AI 개인 맞춤형 신경 조절, EMG 바이오피드백 및 적응형 재활을 위한 증강 현실을 통합한 차세대 플랫폼인 Spatial StimelMD (SSMD)를 개발 중입니다.
ReShape Lifesciences (RSLS) a conclu un accord de distribution exclusif aux États-Unis avec Motion Informatics pour importer et distribuer des dispositifs de réhabilitation neuromusculaire. Le produit phare du partenariat est le Stimel-03, approuvé par la FDA, qui combine la stimulation électrique fonctionnelle, la stimulation électrique neuromusculaire et le biofeedback EMG en temps réel sur une seule plateforme.
Le système est conçu pour les patients en convalescence après un AVC, une blessure ou une chirurgie, et peut être utilisé tant dans des environnements cliniques qu'à domicile. Motion Informatics développe également le Spatial StimelMD (SSMD), une plateforme de nouvelle génération qui intègre la neuromodulation personnalisée par intelligence artificielle, le biofeedback EMG et la réalité augmentée pour une réhabilitation adaptative.
ReShape Lifesciences (RSLS) hat einen exklusiven Vertriebsvertrag in den USA mit Motion Informatics abgeschlossen, um neuromuskuläre Rehabilitationsgeräte zu importieren und zu vertreiben. Das Flaggschiffprodukt der Partnerschaft ist der FDA-zugelassene Stimel-03, der funktionelle elektrische Stimulation, neuromuskuläre elektrische Stimulation und Echtzeit-EMG-Biofeedback in einer einzigen Plattform kombiniert.
Das System ist für Patienten konzipiert, die sich von einem Schlaganfall, einer Verletzung oder einer Operation erholen, und kann sowohl in klinischen als auch in häuslichen Umgebungen eingesetzt werden. Motion Informatics entwickelt auch die Spatial StimelMD (SSMD), eine Plattform der nächsten Generation, die KI-personalisierte Neuromodulation, EMG-Biofeedback und Augmented Reality für adaptive Rehabilitation integriert.
- Exclusive distribution rights secured for FDA-cleared rehabilitation devices in U.S. market
- Strategic expansion into neuromuscular rehabilitation technology sector
- Product portfolio diversification beyond core Lap-Band business
- None.
Insights
ReShape's exclusive U.S. distribution agreement for Motion Informatics' neurorehabilitation technology represents a strategic entry into a growing rehabilitation market. The flagship Stimel-03 device combines three clinically important modalities: Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES), and real-time EMG biofeedback—creating a comprehensive rehabilitation platform.
The technology's clinical value stems from its real-time adaptive capabilities. Traditional rehabilitation devices typically offer either stimulation OR feedback, rarely both in an integrated system. The Stimel-03's FDA clearance removes significant regulatory hurdles, while their next-generation Spatial StimelMD platform introduces AI-personalization that dynamically adjusts to patient response—a meaningful advancement over static protocols.
Particularly noteworthy is the multi-setting deployment capability (clinic, home, telemedicine), addressing the industry's shift toward decentralized care delivery. The closed-loop system that reads patient intent and generates responsive stimulation could potentially improve adherence and outcomes in stroke and injury recovery applications.
For ReShape, this represents diversification beyond weight management into the neuromuscular rehabilitation space—expanding their addressable market while leveraging existing commercial infrastructure. The deal structure (distribution vs. acquisition) limits capital requirements while providing exclusive U.S. market access to differentiated technology.
This partnership marks a calculated diversification move for ReShape beyond its core weight loss solutions business. By securing exclusive U.S. distribution rights to Motion Informatics' rehabilitation technology, ReShape gains immediate access to an adjacent healthcare vertical without the significant R&D investment typically required for such expansion.
The distribution agreement structure offers ReShape several strategic advantages: upfront capital requirements compared to acquisition alternatives, risk mitigation through partnership rather than internal development, and potential revenue diversification through a complementary product line. This approach allows ReShape to test market receptivity while leveraging existing commercial capabilities.
Motion Informatics' technology portfolio—featuring both the FDA-cleared Stimel-03 and pipeline products like the AI-powered Spatial StimelMD—provides ReShape with scalable commercialization opportunities across rehabilitation settings. The technology's applicability across clinical, home, and telemedicine environments aligns with broader healthcare delivery trends toward flexible care models.
While financial terms remain undisclosed (limiting precise impact assessment), this partnership demonstrates management's commitment to strategic portfolio expansion beyond their Lap-Band® franchise. The rehabilitation market's patient population (stroke, injury, surgery recovery) represents a distinct but complementary customer segment that diversifies ReShape's revenue potential while maintaining focus on medical device commercialization.
ReShape Enters Exclusive U.S. Distribution Agreement in the Neuromuscular Rehabilitation Market
IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their next-generation neuromuscular rehabilitation devices in the U.S. The flagship product, the Stimel-03, was showcased at the American Occupational Therapy Association 2025 Annual Conference and Expo, held April 3-5, 2025, in Philadelphia, PA.
“The signing of this agreement with Motion Informatics marks a significant milestone for ReShape as we expand and diversify into rehabilitation technology,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “This partnership presents a unique opportunity to bring cutting-edge, neurorehabilitation solutions to the U.S. market. We are particularly excited to distribute the FDA cleared and commercially available Stimel-03, a breakthrough system that integrates Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES), and real-time electromyographic (EMG) biofeedback into a single, patient-responsive platform—redefining rehabilitation for patients recovering from stroke, injury, or surgery. Motion Informatics’ innovative devices align well with our commitment to improving patient outcomes, complementing our core competencies including commercialization of differentiated products including our Lap-Band® 2.0 FLEX, designed to improve patients’ quality of life while driving meaningful clinical and commercial impact.”
“This partnership accelerates Motion Informatics’ U.S. market strategy by combining ReShape Lifesciences’ commercial reach with our differentiated rehabilitation technologies,” added Gary Sagiv, Chief Executive Officer of Motion Informatics. “Our FDA-cleared Stimel-03 is changing clinical care using real-time EMG biofeedback and personalized electrical stimulation, making it easy to use in both clinic and home settings. Spatial StimelMD (SSMD), our next-generation platform and the first closed-loop neuromotor intelligence system combining AI-personalized neuromodulation, real-time EMG biofeedback, and augmented reality into one adaptive rehabilitation process. The SSMD reads a patient’s intent and generates cadenced stimulation to match, adapting in real-time based on performance, fatigue, and recovery—delivering precise care in clinics, at home, and through telemedicine. Together, these technologies position Motion Informatics and ReShape Lifesciences at the forefront of the neuromuscular rehabilitation market—delivering differentiated capabilities, validated outcomes, and a scalable path to global expansion. We are confident that ReShape is the ideal partner to distribute our products and expand their impact across the U.S.”
About Motion Informatics
Motion Informatics is pioneering next-generation neuromuscular rehabilitation by integrating AI-driven neuroinformatics, augmented reality (AR), and digital health into a seamless, adaptive therapeutic platform. The Company’s Spatial StimelMD (SSMD) leverages personalized real-time electrophysiological data, biofeedback-driven neuromodulation, and AI-optimized intervention protocols to dynamically personalize therapy, enhancing neuroplasticity, motor re-education, and functional recovery in conditions such as stroke, spinal cord injuries, and neuromuscular disorders. By fusing biomechanical modeling, predictive analytics, and remote neurorehabilitation, the Company is redefining precision rehabilitation, creating a highly scalable, intelligent, and data-driven ecosystem that bridges clinical and home-based care. This paradigmshift will establish AI-powered, fully autonomous, and continuously adaptive neuromuscular therapy, fundamentally transforming the future of digital healthcare.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the expectations regarding the distribution arrangement and potential of Motion Informatics’ technology. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
FAQ
What is the new distribution agreement between ReShape Lifesciences (RSLS) and Motion Informatics?
What features does the Stimel-03 rehabilitation device from RSLS offer?
How will the Motion Informatics partnership affect RSLS's market position?
What is the Spatial StimelMD (SSMD) platform that RSLS will distribute?
